- Home
- CANF vs CLRO Comparison
CANF vs CLRO Comparison
Compare CANF & CLRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- CLRO
- Stock Information
- Founded
- CANF 1994
- CLRO 1983
- Country
- CANF Israel
- CLRO United States
- Employees
- CANF N/A
- CLRO N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- CLRO Radio And Television Broadcasting And Communications Equipment
- Sector
- CANF Health Care
- CLRO Technology
- Exchange
- CANF Nasdaq
- CLRO Nasdaq
- Market Cap
- CANF 14.4M
- CLRO 13.9M
- IPO Year
- CANF N/A
- CLRO N/A
- Fundamental
- Price
- CANF $2.01
- CLRO $0.48
- Analyst Decision
- CANF Strong Buy
- CLRO
- Analyst Count
- CANF 2
- CLRO 0
- Target Price
- CANF $14.00
- CLRO N/A
- AVG Volume (30 Days)
- CANF 63.2K
- CLRO 25.2K
- Earning Date
- CANF 11-26-2024
- CLRO 11-15-2024
- Dividend Yield
- CANF N/A
- CLRO 103.82%
- EPS Growth
- CANF N/A
- CLRO N/A
- EPS
- CANF N/A
- CLRO N/A
- Revenue
- CANF $667,000.00
- CLRO $12,584,000.00
- Revenue This Year
- CANF $409.56
- CLRO N/A
- Revenue Next Year
- CANF N/A
- CLRO N/A
- P/E Ratio
- CANF N/A
- CLRO N/A
- Revenue Growth
- CANF N/A
- CLRO N/A
- 52 Week Low
- CANF $1.87
- CLRO $0.48
- 52 Week High
- CANF $4.69
- CLRO $2.48
- Technical
- Relative Strength Index (RSI)
- CANF 38.15
- CLRO 27.19
- Support Level
- CANF $1.93
- CLRO $0.48
- Resistance Level
- CANF $2.21
- CLRO $0.59
- Average True Range (ATR)
- CANF 0.20
- CLRO 0.03
- MACD
- CANF -0.02
- CLRO -0.01
- Stochastic Oscillator
- CANF 15.52
- CLRO 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About CLRO ClearOne Inc. (DE)
ClearOne Inc is a communications solutions company, which is engaged in designing, developing, and selling conferencing, collaboration, streaming, and digital signage solutions for audio, video, and visual communication. It sells its commercial products to end-users predominantly through a network of independent distributors, who in turn sell its products to dealers, systems integrators, and other resellers. Its products include DSP mixers, amplifiers, Video walls, professional cameras, and professional microphones among others. Geographically the firm has its business presence across the United States and international markets.